Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: her2 + herceptin + chromosomes  Related to the article below (Last Update: 8/5/2008)

Will he be able to write fail-safe prescriptions?
The National, United Arab Emirates - Jul 22, 2008
If patients are tested and found to have high levels of this anomaly, they can be treated with a medicine called Herceptin, effective for that specific type ...
Source: Google News

Determination of HER-2 Status and Chromosome 17 Polysomy in Breast Carcinomas Comparing HercepTest … -
D Varshney, YY Zhou, SA Geller, R Alsabeh - American Journal of Clinical Pathology, 2004 - ASCP
... for determining eligibility for trastuzumab treat- ment. ... evaluated the role of
chromosome 17 polysomy ... assessed its relationship to HER-2 protein overexpression ...

Herceptin and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/neu -
H Safran, D Iannitti, R Ramanathan, JD Schwartz, M … - Cancer Investigation, 2004 - informaworld.com
... Herceptin is a monoclonal antibody that targets p185 HER2 , a trans- membrane
glycoprotein receptor encoded by the HER-2/neu gene. [5] Vogel et al. ...

Discrepancies in Clinical Laboratory Testing of Eligibility for Trastuzumab Therapy: Apparent … -
RR Tubbs, JD Pettay, PC Roche, MH Stoler, RB … - Journal of Clinical Oncology, 2001 - jcojournal.org
... and JF Eliason Direct Detection of Herceptin/Trastuzumab Binding on ... for the
determination of true Her-2/neu gene ... CISHTM) in the Evaluation of HER2 Status in ...

Her-2/neu Gene Amplification in Low to Moderately Expressing Breast Cancers: Possible Role of … -
S Bose, M Mohammed, P Shintaku, PN Rao - Breast J, 2001 - Blackwell Synergy
... The Her-2/neu (HER2) oncogene encodes a transmembrane ... method for selecting patients
for trastuzumab (Herceptin) and other modes ... of three to four HER2 copies in ...

Recommendations for HER2 testing in the UK -
IO Ellis, M Dowsett, J Bartlett, R Walker, T Cooke … - British Medical Journal, 2000 - jcp.bmj.com
... Clinic 2000 http://www.digitalclinic.com/herceptin.htm; Press ... Sensitivity of
HER2/neu antibodies in archival tissue ... Her 2 testing in breast cancer?methods of ...

… -p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic … -
MD Pegram, A Lipton, DF Hayes, BL Weber, JM … - Journal of Clinical Oncology, 1998 - jco.ascopubs.org
... Salts, and Trastuzumab in HER2-Positive Advanced ... Interactions between Tamoxifen and
Trastuzumab (Herceptin) Clin. ... Wollscheid, and B. Seliger HER-2/neu-Mediated ...

Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) … -
M Dowsett, J Bartlett, IO Ellis, J Salter, M Hills … - J Pathol, 2003 - doi.wiley.com
... J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene ... in situ hybridisation (FISH)
in the Herceptin Pivotal Trials ... Sahin AA, Ordonez NG, Sneige N. HER2/neu gene ...

HER-2/neu Analysis in Archival Tissue Samples of Human Breast Cancer: Comparison of … -
A Lebeau, D Deimling, C Kaltz, A Sendelhofert, A … - Journal of Clinical Oncology, 2001 - jco.ascopubs.org
... antibody in women who have HER2-overexpressing metastatic ... AK, et al: Correlation
of HER-2/neu amplification ... situ hybridization in the Herceptin pivotal trials. ...

Chromogenic in Situ Hybridization A Practical Alternative for Fluorescence in Situ Hybridization to … -
M Tanner, D Gancberg, A Di Leo, D Larsimont, G … - American Journal of Pathology, 2000 - ASIP
... a 2+ staining result is because of HER-2 gene amplification ... and a likely response
to Herceptin), or because of amplification-unrelated p185 HER2 expression or ...

Assessment of Methods for Tissue-Based Detection of the HER-2/neu Alteration in Human Breast Cancer: … -
G Pauletti, S Dandekar, HM Rong, L Ramos, HJ Peng, … - Journal of Clinical Oncology, 2000 - jco.ascopubs.org
... latter approach was termed the chromosome 17 polysomy ... analysis, confirming that both
HER-2/neu amplification ... that led to approval of trastuzumab, 15 patients ...

Source: Google Scholar

Herceptin Helps Women With Multiple Chromosomes Containing HER2 Gene, Study Finds

SAN ANTONIO — The targeted therapy Herceptin helps women with HER2+ type of breast cancer independent of whether patients have extra copies of chromosome 17, home to the HER2 gene which produces the HER2 protein that fuels cancer growth. Prior to this report, there were conflicting opinions about whether that was the case, say Mayo Clinic investigators who presented their findings at the San Antonio Breast Cancer Symposium.

The analysis came from the North Central Cancer Treatment Group's clinical trial N9831 which tested the use of Herceptin in combination with chemotherapy in patients with surgically-removed HER2+, early-stage, node-positive or high-risk, node-negative breast cancer. Data from the trial on the long term efficacy and safety of this treatment were presented recently by Mayo Clinic researchers and collaborators as part of a joint analysis with another U.S. trial. They demonstrated the significant benefit of using Herceptin, which is a monoclonal antibody that binds the HER2 protein, shutting down its function.

HER2+ breast cancer accounts for approximately 20 percent of all breast cancer cases, and most oncologists decide whether to use Herceptin based on a test that measures the amount of HER2 protein or the number of extra ("amplified") genes in a patient's tumor tissue sample. The goal of this sub-study was to see if patients with more than two chromosome 17s (known as polysomy 17) had a different outcome from use of Herceptin.

"Some oncologists thought that patients with non-amplified HER2 gene in polysomy 17 tumors may respond to Herceptin because they may have that many extra HER2 genes resulting in HER2 protein over expression. Others thought they might not benefit because they had far too many HER2 genes from the extra chromosomes, producing too much HER2 protein, which may overwhelm Herceptin's effectiveness," says the study's lead investigator, Monica M. Reinholz, Ph.D., an assistant professor at Mayo Clinic's campus in Rochester, Minn. "No one knew if they would respond, in general, or not."

The research team, led by Edith A. Perez, M.D., from the Mayo Clinic campus in Jacksonville, Fla., specifically found that 865 patients had HER2 gene amplified tumors with polysomy 17 and 685 women had amplification with two copies (normal) of chromosome 17 did equally well using Herceptin. Their disease-free survival was about 89 percent three years after treatment and between 88 percent and 89 percent five years after therapy, Dr. Reinholz says. "These results of this new analysis suggest that chromosome 17 number status is not predictive of Herceptin response in patients with HER2 amplified tumors," she says.

Also, they found that women with HER2 gene amplification and polysomy 17 who were treated only with chemotherapy seemed to have had a better outcome than patients treated with chemotherapy who did not have the extra chromosomes. Three-year disease-free survival was 83 percent and 75 percent, respectively, and five-year disease-free survival was 78 percent and 68 percent. "This is an interesting and unexpected finding," Dr. Reinholz says.

Researchers also found that 37 patients had HER2 non-amplified and polysomy 17 tumors, and 67 patients had HER2 non-amplified and normal chromosome 17 tumors. There was no apparent influence of polysomy 17 in predicting Herceptin benefit in women with HER2 non-amplified tumors, they say. However, due to the small number of cases in this study, additional patients will be needed to determine whether Herceptin is beneficial in patients with non-amplified HER2 tumors, the researchers say.

The study was funded by Genentech and the Breast Cancer Research Foundation.

###

To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. MayoClinic.com is available as a resource for your health stories.
 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.